Propeller Health announced that it received FDA 510(k) clearance for connecting patients using its Symbicort Inhaler to its digital health platform.
The Madison, Wis.-based company’s digital health platform already connects to inhalers used by asthma and COPD patients, including ones manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, along with other generic equivalents.
Propeller sensors are designed to attach to existing inhalers and deliver insights on medication to the Propeller app on the user’s smartphone. The information delivered to the app can then be shared with clinicians to help inform treatment plans, according to a news release.
The company said its platform has shown in previous clinical studies to increase asthma control by up to 63% and increase medication adherence by up to 58%. It’s also shown to reduce asthma-related emergency department visits and hospitalizations by as much as 57% and reduce COPD-related healthcare utilization by as much as 35%.
“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” Propeller Health co-founder & CEO David Van Sickle said in the release. “This is an important step in transforming the way people receive preventative care, enabling self-management from home and ensuring that providers have the bandwidth to focus on high-risk patients.”